A FDA review of the Bristol-Myers Squibb"s antibiotic, Maxipime [cefepime], has found that it is still an appropriate treatment for its approved indications. The agency began examining data that the drug posed a higher mortality risk than other antibiotics in 2007. Further results are expected in a year as part of ongoing evaluation by the FDA.